|
The manufacturing lot review confirmed all devices met specifications prior to release.The devices were not returned as they remain implanted, and therefore no sample evaluation was completed.A clinical assessment was completed based on the received medical records.The reported type ia endoleak and polymer leak were confirmed.The type ia endoleak was most likely user-related due to the off-label juxtarenal neck angulation of 78 degrees (ifu requirement is less than or equal to 60 degrees).The procedure-related harms identified were hemodynamic instability, respiratory failure (patient reportedly required reintubation post operatively), renal insufficiency (due to hypotension and acute tubular necrosis during the procedure), and a prolonged hospital stay.The postoperative respiratory failure was likely related to the prolonged hypotension in combination with the pre-existing lung disease.The renal insufficiency was most likely related to the prolonged hypotension, and the moderate left renal calcifications could have also contributed.The polymer leak event is most likely device-related as identified in field safety notice (fs-0012); the root cause for most polymer leaks is a material weakness adjacent to the polymer fill channel which may become compromised during pressurization with liquid polymer.Since this device remains implanted, endologix is unable to conduct product evaluation to conclusively ascertain root cause.However, based on the investigation associated with the fsn this is the most likely cause associated with this event.The final patient status was discharged on the sixth postoperative day at home stable.On 06 august 2018, endologix issued a field safety notice (fs-0009) regarding the risk of polymer leak events with the ovation ix aortic body stent graft.On 06 may 2020, endologix issued a follow-up safety update (fs-0012) reaffirming treatment recommendations for patients who experience a polymer leak during implantation and providing updated information on the current rate of polymer leaks, the rate of clinical harms and root cause.No additional investigation of this reported event is planned; however, if additional information pertinent to the incident is obtained, a follow-up report will be submitted.Endologix will continue to monitor this complaint and similar complaints in the event further investigation is needed.Corrections to g4, h6, h9: h6 result code; remove 3233 h6 conclusion code; remove 11.
|